<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thalidomide and lenalidomide belong to the proprietary group of immunomodulatory drugs (IMiDs) that display broad biologic and pharmacologic properties </plain></SENT>
<SENT sid="1" pm="."><plain>Encouraging results of clinical studies that evaluated the efficacy of thalidomide in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs) led to the investigation of its structural analogue, lenalidomide, in patients with lower-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The cumulative results of studies that tested lenalidomide in patients with interstitial deletion of chromosome 5q, ie, del(5q), showed a high frequency of both erythroid and cytogenetic responses (approximately 75% of patients), which led to US Food and Drug Administration approval of this agent for this cytogenetically defined <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subset </plain></SENT>
<SENT sid="3" pm="."><plain>A multicenter phase III study (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-002) that investigated the frequency of transfusion response in lower-risk non-del(5q) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients showed that lenalidomide had significant erythropoietic activity, albeit less robust in lower-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> without del(5q) </plain></SENT>
<SENT sid="4" pm="."><plain>These studies established lenalidomide as an active erythropoietic-remitting agent with novel cytogenetic-remitting activity in lower-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients who would not otherwise benefit from therapy with erythropoietic growth factors </plain></SENT>
<SENT sid="5" pm="."><plain>The National Comprehensive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Network Clinical Practice Guidelines recently added lenalidomide to the therapeutic algorithm for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> as front-line therapy for lower-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with del(5q) and transfusion-dependent <z:hpo ids='HP_0001903'>anemia</z:hpo> </plain></SENT>
</text></document>